Quarterly ResultMay 13, 2026, 04:14 PM
Dermata Therapeutics Reports Going Concern Doubt; Q1 Net Loss $(1.85)M
AI Summary
Dermata Therapeutics reported a net loss of $(1.85) million for Q1 2026, an improvement from $(2.30) million in Q1 2025. However, the company's cash and cash equivalents decreased to $6.9 million, and management expressed substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company is shifting focus to direct-to-consumer skincare products, with the first launch anticipated in mid-2026.
Key Highlights
- Substantial doubt about Dermata Therapeutics' ability to continue as a going concern was reported.
- Net loss for Q1 2026 was $(1.85) million, an improvement from $(2.30) million in Q1 2025.
- Cash and cash equivalents decreased to $6.9 million as of March 31, 2026, from $7.5 million at December 31, 2025.
- Net cash used in operating activities increased to $(2.48) million in Q1 2026 from $(1.93) million in Q1 2025.
- Research and development expenses decreased to $0.38 million in Q1 2026 from $1.28 million in Q1 2025.
- Selling, general and administrative expenses increased to $1.54 million in Q1 2026 from $1.06 million in Q1 2025.
- The company raised approximately $2.0 million net from At The Market (ATM) sales in Q1 2026.
- Dermata Therapeutics is shifting to direct-to-consumer skincare products, with the first launch anticipated in mid-2026.
Price Impact
More from DRMA